Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Core Insights - Puma Biotech reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing a significant improvement from a loss of $0.05 per share a year ago, resulting in an earnings surprise of 400% [1] - The company achieved revenues of $46 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.65% and increasing from $43.8 million year-over-year [2] Earnings Performance - Over the last four quarters, Puma Biotech has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company had an earnings surprise of 207.14% in the previous quarter, where it reported earnings of $0.43 per share against an expectation of $0.14 per share [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $49.38 million, and for the current fiscal year, it is $0.54 on revenues of $216.4 million [7] - The estimate revisions trend for Puma Biotech is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]